Skip to main content
Account

Table 1 Patient and control features.

From: Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus

 

Patients

Controls

Without nephritis

N = 52

With nephritis

N = 48

N = 100

Age (mean ± SD)

43.5 ± 8.4

42.5 ± 11.8

36.8 ± 11.5

Autoantibodies

ANA positive

79%

91%

0%

Anti dsDNA positive

28%

25%

1%

Nephritis

 

48%

 

Without biopsy

 

47%

 

Biopsy grade

II

 

9%

 

III

 

7%

 

IV

 

36%

 

V

 

2%

 

Activity (SLEDAI)

Inactive (0–1.99)

66%

61%

 

Mild (2–3.99)

21%

32%

 

Moderate (4–7.99)

13%

5%

 

Severe (more than 8)

0%

2%

 

Treatment

Hydroxychloroquine monotherapy

72%

42%

 

Hydroxychloroquine in combination

2%

22%

 

Others

4%

7%

 

Without any treatment

21%

29%